Patent · US Active

Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative

US9265835B2 · kind B2 · utility

4Cited by

0References

27Claims

0Family size

Assignee

SHANDONG LUYE PHARMACEUTICAL CO., LTD. · CN

Inventors

Youxin Li · Langenfeld, DE
Aiping Wang · Suzhou, CN
Wanhui Liu · Yantai, CN
Kaoxiang Sun · Yantai, CN
Jun Li · Foster City, US
Lifang Sun · Tianjin, CN

Key dates

Filing date	Nov 25, 2011
Grant date	Feb 23, 2016
Priority date	—
Expiry date	Apr 25, 2032

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P25/16
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The disclosure relates to a composition comprising rotigotine or a pharmaceutically acceptable salt thereof; at least one poly(lactide-co-glycolide) (PLGA); and at least one fatty acid, wherein the at least one fatty acid is at least 0.5% in weight relative to the total weight of the composition. The composition as disclosed herein has significantly reduced burse release effect. The disclosure also provides a method of treating Parkinson's disease comprising administering an effective amount of the composition as disclosed to a subject in need thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.